English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

Objectives  c-Met is a receptor tyrosine kinase shown inappropriate expression and actively involved in progression and metastasis in most types of human cancer. Development of c-Met-targeted imaging and therapeutic agents would be extremely useful. Previous studies reported that c-Met-binding peptide (Met-pep1,  YLFSVHWPPLKA ) specifically targets c-Met receptor. Here, we evaluated  18 F-labeled Met-pep1 for PET imaging of c-Met positive tumor in human head and neck squamous cell carcinoma (HNSCC) xenografted mice.    Methods  c-Met-binding peptide, Met-pep1, was synthesized and labeled with 4-nitrophenyl [ 18 F]-2-fluoropropionate ([ 18 F]-NPFP) ([ 18 F]FP-Met-pep1). The cell uptake, internalization and efflux of [ 18 F]FP-Met-pep1 were assessed in UM-SCC-22B cells.  In vivo  pharmacokinetics, blocking and biodistribution of the radiotracers were investigated in tumor-bearing nude mice by microPET imaging.    Results  The radiolabeling yield for [ 18 F]FP-Met-pep1 was over 55% with 97% purity. [ 18 F]FP-Met-pep1 showed high tumor uptake in UM-SCC-22B tumor-bearing mice with clear visualization. The specificity of the imaging tracer was confirmed by significantly decreased tumor uptake after co-administration of unlabeled Met-pep1 peptides. Prominent uptake and rapid excretion of [ 18 F]FP-Met-pep1 was also observed in the kidney, suggesting this tracer is mainly excreted through the renal-urinary routes.  Ex vivo  biodistribution showed similar results that were consistent with microPET imaging data.    Conclusions  These results suggest that  18 F-labeled c-Met peptide may potentially be used for imaging c-Met positive HNSCC cancer  in vivo  and for c-Met-targeted cancer therapy.

Imaging c-Met expression using 18F-labeled binding peptide in human cancer xenografts